Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
Bullboard Posts
User Avatar Image
(186)
•••
Comment by robertshawon Oct 24, 2017 7:59pm
162 Views
Post# 26853577

RE:RE:RE:RE:Interesting comment by Dr. McFarland ... ;-)

RE:RE:RE:RE:Interesting comment by Dr. McFarland ... ;-)
skier59 wrote: Yup, that's a very powerful statement :)

wildbird1 wrote:
Bencro... this is huge....

Before she made that comment Dr: McFarland's had access to the first 30 days, safety, tolerability, and pharmacokinetics (movement and exit of drug within tissue), and exploratory endpoint of efficacy.

Bencro you made my day...

bencro wrote: Knowing that patient #4 had been treated July 20th and that its 30-days for potential adverse events ended August 20th and that Dr. McFarland's posted this on August 23rd, things look interesting ... ;-)

Too bad this doesn't come from Bunge, Woundedknee or Langosta ... ;-)
Probably non-related stuff, as per Woundedknee and Bunge! ... ;-)

_____________________

bencro - (10/24/2017 4:15:29 PM) 
Interesting comment by Dr. McFarland ... ;-)
Interesting comment by Dr. McFarland on her UNCG web site ... ;-) 

It smells total confidence!



CLINICAL TRIAL NEWS

A fourth patient has been successfully treated with TLD1433.Your days are numbered, bladder cancer!


Source: McFarland Research Group | Just another Department of Chemistry and Biochemistry Sites site






I think it is safe to say: basement boys and their pharcking boss' days are numbered..... Any one agree with me, please give me 5... I know basement boy would give me lonely star for sure, but I deem that's a honor.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities